Product information and disease descriptionProduct description
Phase of product development
13 evidence topics · 9 sources
Regulatory status: Submission planned; BLA planned, with topline pivotal interim data and FDA feedback on the submission pathway expected in the first half of 2027
Launch
No evidence found.
Development stage: dosing complete in the pivotal and ASPIRE trials
Breakthrough Therapy designation: September 2025
Regenerative Medicine Advanced Therapy designation: April 2024
Orphan drug and rare pediatric disease designations: FDA, October 2020
| Field | Quoted record |
|---|---|
| Generic name | “recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene” |
| Orphan designation | “Treatment for Rett syndrome” |
| Designation date | “10/07/2020” |
| Designation status | “Designated” |